Xortx Therapeutics INC 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
XORTX Therapeutics Inc. reported significant net losses for 2025, acquired a new renal therapeutic program, and received a Nasdaq delisting notice while also identifying a material weakness in internal controls.
NASDAQ
XORTX Therapeutics Inc. files its 20-F report, outlining financial performance and progress in its drug development programs, particularly highlighting the XRx-026 gout treatment and interactions with the FDA.
NASDAQ
XORTX Therapeutics amends a consulting agreement and proposes changes to warrant terms to enhance public awareness and financial flexibility.